본문 바로가기

Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review

문서 유형
연구출판물 · 리뷰논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY24(3) · pp.278 · 2020
피인용
Web of Science 11Scopus 12
FWCI (Scopus)
0
JCR IF
JCR 2019 1.909
ISSN
1203-4754

저자

  1. 김병수제1저자Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
  2. Maverakis, EmanualDepartment of Dermatology, University of California School of Medicine, Davis, CA, USA
  3. Alexanian, ClarieDepartment of Dermatology, University of California School of Medicine, Davis, CA, USA
  4. Wang, Jenny Z.Department of Dermatology, University of California School of Medicine, Davis, CA, USA
  5. Raychaudhuri, Siba P.교신저자VA Medical Center Sacramento, Division of Rheumatology Immunology, Mather, CA, USA

초록

Tumor necrosis factor (TNF) inhibitors have been used as an excellent therapeutic option in a variety of chronic inflammatory conditions. However, a recognized significant adverse effect of TNF inhibitor therapy is the increased risk of infections. The influence of TNF inhibitors on the course of coexisting or newly developed viral infections has not been extensively investigated. Therefore, we reviewed the recent publications to highlight the incidence, clinical features, management, and prevention of herpes zoster in patients who are receiving TNF inhibitors.

키워드

herpes zosteranti-TNF therapyTNF inhibitorsTNF antagonistsvaccinationvaricella zoster virusANTI-TNF-ALPHAFACTOR MONOCLONAL-ANTIBODYRHEUMATOID-ARTHRITISPOSTHERPETIC NEURALGIAFACTOR ANTAGONISTSBRITISH SOCIETYRISKINFECTIONSADALIMUMABTUBERCULOSIS

식별자

Scopus EID
2-s2.0-85083277525
WoS UID
000523530900001